The DP15 facility at the company's Fengxian site adds isolator-based aseptic filling for liquid and lyophilized drug products to support clinical-stage programs.
The platform combines inducible transgene control with a tetherin-based selection system to improve genetic stability and reduce purification steps in MVA manufacturing.
